Wei He

US Patent:

62457608, Jun 12, 2001

Filed:

Nov 24, 1998

Appl. No.:

9/198720

Inventors:

Wei He - Collegeville PA
Michael R. Myers - Reading PA
Alfred P. Spada - Lansdale PA

Assignee:

Aventis Pharmaceuticals Products, Inc - Bridgewater NJ

International Classification:

A61K 31498
C07D24140

US Classification:

5142348

Abstract:

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56. sup. lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

US Patent:

20200323885, Oct 15, 2020

Filed:

Feb 13, 2020

Appl. No.:

16/790197

Inventors:

- Hangzhou, CN
Wei He - Audubon PA, US

Assignee:

ZHEJIANG DTRM BIOPHARMA CO. LTD. - Hangzhou

International Classification:

A61K 31/635
A61K 45/06
A61K 31/519
C07D 487/04
A61P 35/00
A61K 31/52
A61K 31/436
A61K 31/454

Abstract:

Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.

US Patent:

20200289517, Sep 17, 2020

Filed:

Oct 26, 2018

Appl. No.:

16/763483

Inventors:

- Hangzhou, Zhejiang Province, CN
Wei He - Audubon PA, US

Assignee:

ZHEJIANG DTRM BIOPHARMA CO. LTD. - Hangzhou, Zhejiang Province

International Classification:

A61K 31/519
A61K 31/436
A61K 31/4439
A61P 35/02

Abstract:

The present disclosure provides methods of treating lymphoid malignancies such as B cell malignancies using a BTK inhibitor in the described therapeutic regimens.

US Patent:

20190192541, Jun 27, 2019

Filed:

Sep 6, 2018

Appl. No.:

16/123203

Inventors:

- Hangzhou, CN
Wei He - Audubon PA, US

International Classification:

A61K 31/635
C07D 487/04
A61K 31/519
A61K 45/06
A61K 31/454
A61K 31/436
A61K 31/52
A61P 35/00

Abstract:

Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.

US Patent:

20180360853, Dec 20, 2018

Filed:

Sep 6, 2018

Appl. No.:

16/123167

Inventors:

- Hangzhou, CN
Wei He - Audubon PA, US

Assignee:

ZHEJIANG DTRM BIOPHARMA CO. LTD. - Hangzhou

International Classification:

A61K 31/635
C07D 487/04
A61K 31/519
A61K 31/436
A61K 45/06
A61P 35/00
A61K 31/454
A61K 31/4162

Abstract:

Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.

US Patent:

20180207161, Jul 26, 2018

Filed:

Nov 22, 2017

Appl. No.:

15/820614

Inventors:

- SHANGHAI, CN
Wei He - Audubon PA, US

Assignee:

ZHEJIANG DTRM BIOPHARMA CO. LTD. - SHANGHAI

International Classification:

A61K 31/519
C07F 5/02
C07F 5/04
C07D 519/00
C07D 487/04
C07C 311/08
C07C 303/38

Abstract:

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

US Patent:

20170281810, Oct 5, 2017

Filed:

Jun 20, 2017

Appl. No.:

15/628143

Inventors:

- Shanghai, CN
Wei He - Audubon PA, US

International Classification:

A61K 45/06
A61K 31/519

Abstract:

Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.

US Patent:

20170065594, Mar 9, 2017

Filed:

Nov 18, 2016

Appl. No.:

15/356014

Inventors:

Wei He - Audubon PA, US

Assignee:

Zhejiang DTRM Biopharma Co. Ltd. - Shanghai

International Classification:

A61K 31/519

Abstract:

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.